Valpromide
SIGMA/V3640 - ≥97% (NMR)
Synonym: 2-Propylvaleramide; 2-propyl-pentanamide; Depamid; Depamide; Di-n-propylacetamide; Dipropylacetamide
CAS Number: 2430-27-5
Empirical Formula (Hill Notation): C8H17NO
Molecular Weight: 143.23
MDL Number: MFCD00051534
Linear Formula: C8H17NO
Product Type: Chemical
| assay | ≥97% (NMR) |
| color | white to off-white |
| form | powder |
| InChI | 1S/C8H17NO/c1-3-5-7(6-4-2 |
| InChI key | OMOMUFTZPTXCHP-UHFFFAOYSA |
| originator | Sanofi Aventis |
| Quality Level | 100  |
| SMILES string | CCCC(CCC)C(N)=O |
| solubility | DMSO: >10 mg/mL |
| storage temp. | room temp |
| Application: | Valpromide has been used to pretreat NIH/3T3 cells to test its effect on cytomegalovirus (CMV) viral replication. It has also been used to test its antiviral functionality in herpes simplex virus type 1 (HSV-1) infected human oligodendroglioma (HOG) cells. It may be used to test its effect on apoptosis induction in astrocytes. |
| Biochem/physiol Actions: | Valpromide (VPD) is a derivative of valproic acid (VPA) and is used as an antiepileptic drug. It is hydrolyzed quickly to VPA in vivo, but has intrinsic anticonvulsant activity. |
| Biochem/physiol Actions: | Valpromide possesses antipsychotic property. It lacks the toxic and teratogenic effects of valproic acid. It also lacks the histone deacetylase (HDAC) inhibitory activity of valproic acid. |
| Features and Benefits: | This compound was developed by Sanofi Aventis . To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here . |
| Packaging: | 10, 50 mg in glass bottle |
| Symbol |  GHS07 |
| Signal word | Warning |
| Hazard statements | H302 |
| Precautionary statements | P264 - P270 - P301 + P312 + P330 - P501 |
| Hazard Codes | Xn |
| Risk Statements | 22 |
| RIDADR | NONH for all modes of transport |
| WGK Germany | WGK 3 |
| Flash Point(F) | Not applicable |
| Flash Point(C) | Not applicable |
| Purity | ≥97% (NMR) |
| Storage Temp. | room temp |
| UNSPSC | 12352200 |